Skip to main content

Table 2 Non-relapse mortality according to treatment regimen

From: Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

  t-IV Bu/Flu Bu/Cy
100 days 3% 16%
6 months 7% 18%
1 year 15% 25%